European leader in the production and commercialisation of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) radiopharmaceuticals and is able to produce and deliver both commercial drugs and research products.
For 30 years, we have worked for leading edge companies and organizations involved in a wide range of emerging technologies
Accure Therapeutics, a private pharma R&D engine at clinical stage in the CNS field, was launched in 2020 with a Series A funding led by Alta Life Sciences and supported by the Centre for Technological and Industrial Development (CDTI).
Specialized in the discovery of new Biomarkers and the development of innovative Diagnostics focused on personalized medicine applications.
French association of biotechnology companies. Supported by French ministries, Adebiotech organizes interactions between biotechnology companies to promote and support responsible innovations.
Advanced BioDesign is a French biotechnology company developing an innovative targeted therapy to treat resistant cancers, with a first indication in acute myeloid leukemia.
Advent France Biotechnology focuses on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies
Biotechnology company focused on the development of a therapeutic HIV vaccine to be used as part of a cure/eradication strategy.
Alaxia, an affiliate of the Stragen Pharma Group, specializes in developing antimicrobial therapies for cystic fibrosis and other chronic respiratory diseases.
Specialised engineering for the global aerospace, automotive, and commercial transportation markets producing high quality, wide application fastening system solutions.
Alderaan Biotechnology is a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer with technologies aiming at Treg depletion and NK cell modulation.
Group composed of privately-held biopharmaceutical companies specialised in the development of innovative therapeutics for the treatment of metabolic diseases and cancer.
Alizé Pharma 3 develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Its ambition is to become a leading company in rare diseases with operations in the US and Europe, geared to supporting the global development of products.